Work

Two-Year (yr) Follow-up (FU) of Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphomas (LBCL)

Year: 2022

Type: article

Source: Transplantation and Cellular Therapy

DOI: 10.1016/s2666-6367(22)00226-3

Authors: Jeremy S. Abramson, M. Lia Palomba, Leo I. Gordon, Matthew Lunning, Michael Wang, Jon E. Arnason, Enkhtsetseg Purev, David G. Maloney, Charalambos Andreadis, Alison R. Sehgal, Scott R. Solomon, Nilanjan Ghosh, Ana Kostic, Yeonhee Kim, Ken Ogasawara, Christine Dehner, Tanya Siddiqi

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $3,650

OpenAlex ID: W4220839910

FWCI: 0.105

Cites:

Cited by: 1

Related to: 10